Diagnostic Deals: Urgent Need for Coronavirus Diagnostics Fuels Strategic Collaboration
Not surprisingly, teaming up for development and commercialization of coronavirus (COVID-19) detection and vaccination products was a major theme of strategic alliance making during the period. Notable deals included: The collaboration between Curetis Group company Ares Genetics and China-based BGI Group to bring the latter’s newly CE-marked COVID-19 molecular test to the European market via an NGS testing service launched by Ares using BGI reagents; The pairing of LGC Biosearch Technologies with diagnostics software developer UgenTec on a research-use-only AI-based coronavirus detection workflow; Expansion of the current joint development agreement between Takis Biotech and DNA Sciences subsidiary LineaRx to preclinical development of a linear DNA vaccine for COVID-19; and Johnson & Johnson’s new partnership with the U.S. Biomedical Advanced Research and Development Authority (BARDA) for accelerated development of a coronavirus vaccine. The Month in M&A M&A activity was sluggish in February, in terms of both deal volume and value. The deals that did take place were largely modest in scope and at undisclosed prices. Among the transactions for which purchase price was reported, Meridian Bioscience’s acquisition of Israeli GI and liver diagnostics firm Exalenz Bioscience was the most expensive at 6.10 shekels per share and 169 million shekels in total […]
Not surprisingly, teaming up for development and commercialization of coronavirus (COVID-19) detection and vaccination products was a major theme of strategic alliance making during the period. Notable deals included:
- The collaboration between Curetis Group company Ares Genetics and China-based BGI Group to bring the latter’s newly CE-marked COVID-19 molecular test to the European market via an NGS testing service launched by Ares using BGI reagents;
- The pairing of LGC Biosearch Technologies with diagnostics software developer UgenTec on a research-use-only AI-based coronavirus detection workflow;
- Expansion of the current joint development agreement between Takis Biotech and DNA Sciences subsidiary LineaRx to preclinical development of a linear DNA vaccine for COVID-19; and
- Johnson & Johnson’s new partnership with the U.S. Biomedical Advanced Research and Development Authority (BARDA) for accelerated development of a coronavirus vaccine.
The Month in M&A
M&A activity was sluggish in February, in terms of both deal volume and value. The deals that did take place were largely modest in scope and at undisclosed prices. Among the transactions for which purchase price was reported, Meridian Bioscience’s acquisition of Israeli GI and liver diagnostics firm Exalenz Bioscience was the most expensive at 6.10 shekels per share and 169 million shekels in total ($49 million). The deal, which is expected to close in the second quarter, will enable Meridian to bolster its stool antigen product line via addition of Exalenz’ BreathID Breath Test Systems, a, a point-of-care urea breath test platform for H. pylori detection.
In releasing its 2019 fourth quarter earnings, Exact Sciences disclosed that it had made a strategic move in the cancer diagnostics space via a pair of acquisitions:
- NGS-based cancer diagnostic test maker for therapy selection Paradigm Diagnostics; and
- Viomics, a molecular firm specializing in biomarker selection for cancer diagnostics.
Here’s a summary of the key M&A and other strategic diagnostic deals announced from late January through February:
MERGERS, ACQUISITIONS & ASSET SALES | ||
Acquiring Company | Target(s) | Deal Summary |
Meridian Bioscience | Exalenz Bioscience |
|
P4 Diagnostix | Strand Diagnostics |
|
Quest Diagnostics | Memorial Hermann Health System |
|
Exact Sciences | Paradigm Diagnostics |
|
Exact Sciences | Viomics |
|
OncoCyte | Insight Genetics |
|
Abcam | Applied StemCell |
|
Sysmex | Astrego Diagnostics |
|
Predictive Oncology | Quantitative Medicine |
|
STRATEGIC ALLIANCES, PARTNERSHIPS & COLLABORATIONS | ||
Partner 1 | Partner(s) 2+ | Deal Summary |
BGI Group | Ares Genetics (part of Curetis Group) |
|
UgenTec | LGC Biosearch Technologies |
|
Thermo Fisher Scientific | NanoPin Technologies |
|
Thermo Fisher Scientific | Q-linea |
|
Becton Dickinson | Babson Diagnostics |
|
Lucid Diagnostics | Fred Hutchinson Cancer Research Center |
|
Namocell | HepaTx + Takara Bio |
|
Euformatics | Bio.logis |
|
Advaxis | Personalis |
|
CosmosID | Bioeostasis |
|
ProSciento | Nordic Bioscience |
|
Predictive Technology Group | Atrin Pharmaceuticals |
|
Cellectricon | StressMarq Biosciences |
|
Biodesix | Streck |
|
Sysmex | Riken Innovation |
|
Jackson Laboratory | Shriners Hospitals for Children |
|
DISTRIBUTION, SALES & MARKETING AGREEMENTS | ||
Property Owner | Distributor | Deal Summary |
Molecular Biology Systems | Velocidy Bio |
|
Sienna Cancer Diagnostics | Immuno Diagnostic |
|
Curetis | Quaphaco |
|
Inex Innovate | Inalways |
|
LICENSES | ||
Licensor | Licensee | Deal Summary |
Agilent Technologies | Twist Bioscience |
|
ERS Genomics | Aelian Biotechnology |
|
NEW CLINICAL STUDIES | ||
DX Partner | Other Partner(s) | Description of Study |
Foundation Medicine + Chugai Pharmaceutical |
National Cancer Center Japan |
|
Natera | Elicio Therapeutics |
|
SUPPLY, SERVICE & TESTING AGREEMENTS | ||
Supplier/Servicer | Client/User | Deal Summary |
Siemens Healthineers | Quest Diagnostics |
|
Subscribe to view Essential
Start a Free Trial for immediate access to this article